Furthermore, most of the patients with T2DM on dialysis receive exogenous insulin, which can further increase circulating insulin and CP levels, contributing to visceral adiposity (EAT) and microvascular damage (CAC). This evidence concerns the gene INS and type 2 diabetes mellitus.